ATP citrate lyase Inhibitors
2 drugsAbout ATP citrate lyase
ATP-citrate lyase (ACLY) catalyzes the conversion of citrate and CoA to oxaloacetate and acetyl-CoA, a key building block for fatty acid and cholesterol synthesis. The enzyme plays a crucial role in lipid metabolism within the cytoplasm.
ACLY is a drug target in the metabolic therapeutic area due to its involvement in lipid production. Currently, there is no genetic evidence directly linking ACLY to specific diseases, but its role in lipid metabolism makes it a compelling target.
ACLY is targeted by two FDA-approved small molecule drugs, NEXLIZET and NEXLETOL, both from ESPERION THERAPS INC. These drugs highlight the potential of ACLY inhibition for therapeutic benefit in metabolic indications.
Top ATP citrate lyase Drugs
ESPERION THERAPS INC is the only company with approved drugs targeting ACLY.
High market concentration suggests significant entry barriers or limited commercial interest.
ATP citrate lyase Drug Modality Landscape
Modalities
Routes of Administration
ATP citrate lyase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies to differentiate from existing therapies.
ATP citrate lyase Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ATP citrate lyase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 0 | 2 | 100% |
| Phase 3 | 14 | 9 | 0 | 5 | 100% |
| Phase 4 | 6 | 3 | 1 | 2 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ATP citrate lyase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ATP citrate lyase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
ATP citrate lyase Drug Approval Timeline (2020 - 2020)
The first drug targeting ACLY was approved in 2020, with the most recent approval also in 2020.
Recent approvals indicate a renewed interest, but saturation may occur quickly.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 16 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ATP citrate lyase. A trial counts if an approved drug acting on ATP citrate lyase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.